Javascript must be enabled to continue!
4-1BBL Reverse Signaling Enhances Proliferation of Human Multiple Myeloma Cell Line U266
View through CrossRef
Abstract
Abstract 5074
Multiple myeloma is an incurable plasma cell malignancy. Unraveling the intricate pathobiology and exploitation of novel therapeutic approaches are needed. 4-1BBL, a member of the tumor necrosis factor family, cross-links its receptor, 4-1BB, and co-stimulates T cell activities. Recent studies confirm that 4-1BB-4-1BBL interaction generates bi-directional signals. 4-1BBL has been detected on many tumor cells, and many tumor microenvironmental cells express 4-1BB molecule. However, whether the reverse signaling through 4-1BBL participates the pathology of multiple myeloma is unknown. In this study, we identify the constitutive expression of 4-1BBL on U266, LP1, MY5 and OPM2 MM cell lines as 89.2%, 57.9%, 77.9% and 78.7%. Then we select U266 cell to explore the biological effect of 4-1BBL reverse signaling and its underlying mechanism. Triggered by anti-4-1BBL mAb (1F1), cell counting and MTT assay both demonstrated that U266 cell proliferation increased dramatically. Intracellular cytokine staining showed that treatment of cells with 1F1 also increased the production of IL-6. When neutralizing anti-IL-6 mAb was added to the culture medium, 1F1-induced U266 cell proliferation was effectively inhibited. These effects of 4-1BBL require immobilization of 1F1 but not soluble form. Taken together, 4-1BBL reverse signaling promotes U266 cell proliferation remarkably while increasing the production of IL-6. Moreover, neutralizing anti-IL-6 mAb inhibits U266 cell proliferation stimulated by mAb 1F1, supporting that 4-1BBL reverse signaling promotes the proliferation of U266 cell through increasing the production of IL-6.
Disclosures:
No relevant conflicts of interest to declare.
Title: 4-1BBL Reverse Signaling Enhances Proliferation of Human Multiple Myeloma Cell Line U266
Description:
Abstract
Abstract 5074
Multiple myeloma is an incurable plasma cell malignancy.
Unraveling the intricate pathobiology and exploitation of novel therapeutic approaches are needed.
4-1BBL, a member of the tumor necrosis factor family, cross-links its receptor, 4-1BB, and co-stimulates T cell activities.
Recent studies confirm that 4-1BB-4-1BBL interaction generates bi-directional signals.
4-1BBL has been detected on many tumor cells, and many tumor microenvironmental cells express 4-1BB molecule.
However, whether the reverse signaling through 4-1BBL participates the pathology of multiple myeloma is unknown.
In this study, we identify the constitutive expression of 4-1BBL on U266, LP1, MY5 and OPM2 MM cell lines as 89.
2%, 57.
9%, 77.
9% and 78.
7%.
Then we select U266 cell to explore the biological effect of 4-1BBL reverse signaling and its underlying mechanism.
Triggered by anti-4-1BBL mAb (1F1), cell counting and MTT assay both demonstrated that U266 cell proliferation increased dramatically.
Intracellular cytokine staining showed that treatment of cells with 1F1 also increased the production of IL-6.
When neutralizing anti-IL-6 mAb was added to the culture medium, 1F1-induced U266 cell proliferation was effectively inhibited.
These effects of 4-1BBL require immobilization of 1F1 but not soluble form.
Taken together, 4-1BBL reverse signaling promotes U266 cell proliferation remarkably while increasing the production of IL-6.
Moreover, neutralizing anti-IL-6 mAb inhibits U266 cell proliferation stimulated by mAb 1F1, supporting that 4-1BBL reverse signaling promotes the proliferation of U266 cell through increasing the production of IL-6.
Disclosures:
No relevant conflicts of interest to declare.
Related Results
Fine Tuning Bispecific Activity in CLL: Harmonizing a CD19/20-T Cell Bispecific with a CD28 or 4-1BBL Costimulatory Bispecific
Fine Tuning Bispecific Activity in CLL: Harmonizing a CD19/20-T Cell Bispecific with a CD28 or 4-1BBL Costimulatory Bispecific
Introduction:
T cell bispecific antibodies (TCBs), such as blinatumomab, mosunetuzumab or glofitamab, redirect T cells toward cancer cells and rely on endogenous T c...
Galectin-1 Can Support the Survival of Human Myeloma Cells in In Vitro Culture.
Galectin-1 Can Support the Survival of Human Myeloma Cells in In Vitro Culture.
Abstract
Myeloma cells as well as other hematopoietic cells exist in the bone marrow (BM), where adhesion molecules, cytokines and chemokines may play very important...
Abstract 5548: Novel small-molecule delta opioid receptor ligands modeled from naltrindole inhibit the proliferation of human U266 multiple myeloma cells.
Abstract 5548: Novel small-molecule delta opioid receptor ligands modeled from naltrindole inhibit the proliferation of human U266 multiple myeloma cells.
Abstract
Multiple myeloma is an invasive plasma cell neoplasm that proliferates in the bone marrow, and is responsible for 10% of all hematological malignancies. Nal...
Augmenting Efficacy of T-Cell Bispecific Antibodies in AML through a Tumor Stroma-Targeted 4-1BB Agonist
Augmenting Efficacy of T-Cell Bispecific Antibodies in AML through a Tumor Stroma-Targeted 4-1BB Agonist
Abstract
Bispecific antibodies represent a promising treatment option for acute myeloid leukemia (AML). We have recently described a novel T-cell bispecific antibody...
Complex Collision Tumors: A Systematic Review
Complex Collision Tumors: A Systematic Review
Abstract
Introduction: A collision tumor consists of two distinct neoplastic components located within the same organ, separated by stromal tissue, without histological intermixing...
Seorang laki-laki dewasa muda dengan multiple myeloma monoklonal gamopati lambda: sebuah laporan kasus
Seorang laki-laki dewasa muda dengan multiple myeloma monoklonal gamopati lambda: sebuah laporan kasus
Introduction: Multiple myeloma is the second most common hematological malignancy after non-Hodgkin's lymphoma with a case prevalence in Prof. Dr. I.G.N.G. Ngoerah Hospital for the...
Data from Functional B7.2 and B7-H2 Molecules on Myeloma Cells Are Associated with a Growth Advantage
Data from Functional B7.2 and B7-H2 Molecules on Myeloma Cells Are Associated with a Growth Advantage
<div>Abstract<p><b>Purpose:</b> B7 family molecules expressed on antigen-presenting cells stimulate or inhibit normal immune responses. The aim of this stud...
Data from Functional B7.2 and B7-H2 Molecules on Myeloma Cells Are Associated with a Growth Advantage
Data from Functional B7.2 and B7-H2 Molecules on Myeloma Cells Are Associated with a Growth Advantage
<div>Abstract<p><b>Purpose:</b> B7 family molecules expressed on antigen-presenting cells stimulate or inhibit normal immune responses. The aim of this stud...

